Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin Dose Escalation for Glabellar Rhytids
NCT01583478Phase 4Unknown
- Sponsor
- The Maas Clinic
- Start
- Sep 2014
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of botulinum toxin type A in glabellar lines (5 arms), sponsored by The Maas Clinic. Primary endpoint: Efficacy of escalating doses of Xeomin in the treatment of glabellar rhytids at 12 months. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT01583478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01583478.